首页> 外文期刊>Biological research: BR >Mast cells-derived MiR-223 destroys intestinal barrier function by inhibition of CLDN8 expression in intestinal epithelial cells
【24h】

Mast cells-derived MiR-223 destroys intestinal barrier function by inhibition of CLDN8 expression in intestinal epithelial cells

机译:肥大细胞衍生的miR-223通过抑制肠上皮细胞中的CLDN8表达来破坏肠道阻隔功能

获取原文
           

摘要

Mast cells (MCs) have been found to play a critical role during development of inflammatory bowel disease (IBD) that characterized by dysregulation of inflammation and impaired intestinal barrier function. However, the function of MCs in IBD remains to be fully elucidated. In our study, we used exosomes isolated from human mast cells-1 (HMCs-1) to culture with NCM460, HT-29 or CaCO2 of intestinal epithelial cells (IECs) to investigate the communication between MCs and IECs. We found that MCs-derived exosomes significantly increased intestinal epithelial permeability and destroyed intestinal barrier function, which is attributed to exosome-mediated functional miRNAs were transferred from HMCs-1 into IECs, leading to inhibit tight junction-related proteins expression, including tight junction proteins 1 (TJP1, ZO-1), Occludin (OCLN), Claudin 8 (CLDN8). Microarray and bioinformatic analysis have further revealed that a panel of miRNAs target different tight junction-related proteins. Interestingly, miR-223 is enriched in mast cell-derived exosome, which inhibit CLDN8 expression in IECs, while treatment with miR-223 inhibitor in HT-29 cells significantly reversed the inhibitory effect of HMCs-1-derived exosomes on CLDN 8 expression. Most importantly, enrichment of MCs accumulation in intestinal mucosa of patients with IBD compared with those healthy control. These results indicated that enrichment of exosomal miR-223 from HMCs-1 inhibited CLDN8 expression, leading to destroy intestinal barrier function. These finding provided a novel insight of MCs as a new target for therapeutic treatment of IBD.
机译:已发现肥大细胞(MCS)在炎症性肠病(IBD)的发展期间发挥着关键作用,其特征在于炎症的失调和肠道阻隔功能受损。但是,IBD中MCS的功能仍然是完全阐明的。在我们的研究中,我们使用从人肥大细胞-1(HMCS-1)中分离的外索体与肠上皮细胞(IEC)的NCM460,HT-29或CaCO2培养,以研究MCS和IEC之间的沟通。我们发现MCS衍生的外泌体显着增加肠上皮渗透性和破坏的肠道阻隔功能,其归因于外科介导的功能MiRNA从HMCS-1转移到IEC中,导致抑制紧密结合相关的蛋白质表达,包括紧密结蛋白1(TJP1,ZO-1),Occludin(OCLN),Claudin 8(CLDN8)。进一步揭示了微阵列和生物信息分析,其中一组miRNA靶向不同的紧密结合相关蛋白。有趣的是,MiR-223富集在肥大细胞衍生的外泌体中,其抑制IECS中的CLDN8表达,同时用HT-29细胞的miR-223抑制剂治疗显着逆转了HMCS-1-衍生的外索体对CLDN 8表达的抑制作用。最重要的是,与那些健康对照相比,IBD患者肠粘膜中MCS积累的富集。这些结果表明,来自HMCS-1的外泌体miR-223的富集抑制了CLDN8表达,导致破坏肠道阻隔功能。这些发现提供了对MCS的新颖洞察力作为IBD治疗治疗的新目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号